Can-fite Biopharma Ltd(CANF)stock report

Can-fite Biopharma Ltd., founded on September 11, 1994, is a clinical stage Biopharma company specializing in the development of oral Biopharma products for the treatment of autoimmune inflammation, cancer and eye disease. The platform technology utilizes Gi protein-related A 3 AR as A therapeutic target. A 3 AR altimeter is present in inflammatory and cancer cells, but not in normal cells, suggesting that this receptor could be A unique target for drug intervention. The pipeline drugs are synthetic and belong to highly specific receptor agonists and allosteric regulators, ligands or molecules that initiate molecular events when they target A 3 AR and bind to the target protein.

Highlights:
$CANF and Univo Pharmaceuticals Collaboration Result in Discovery and Applied Patent for Cannabinoid Formulations with Broad Therapeutic Effects

Finance:
Market Cap:13.8MM; Shares Outstanding:4.0M; Q2 2019(6/30/19): Cash 3.21M. Loss 3.06M

EPS and Sales:
https://finance.yahoo.com/quote/CANF/financials?p=CANF

Date EPS % last year % last quarter
 2018.3.31 -0.05 / 280.00%
 2018.6.30 -0.08 20.00% -60.00%
2018.12.31 -0.17 10.53% -112.50%
2019.3.31 -0.04 20.00% 76.47%

 

Date Sales % last year % last quarter
 2018.3.31 0.63M / -20.25%
 2018.6.30 0.9M 563.24% 42.86%
2018.12.31 3.82M 384.16% 324.44%
2019.3.31 0.3M -52.69% -92.15%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=CANF&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/CANF/institutional-ownership/

2019.12.28:
Total institutions: 11,no change
Shares hold: 159.1k shares. no change
shares% hold: 3.99%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/CANF/price-targe

Leave a Reply